NEWS AND ANNOUNCEMENTS
Three-year Data from INTREPID Study Shows Favorable Safety Profile — Commercial Adaptation of Oraya Therapy Continues to Grow.

Full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone.
More >

Oraya Therapy Expansion Release

home_map

The Oraya Therapy is now available in Germany, Switzerland and the United Kingdom. Additional locations coming soon. For more information, call 0800-690-6495 in the United Kingdom and in Germany call 0800-283-2243.

TreatmentCenters_sm

Oraya Therapy Centers
BBC Look North – September 2014

 
BBC-LookNorth-clip

Press Release: First National Health Service hospital in UK and four prestigious hospitals in Germany adopt Oraya Therapy to maintain vision with reduced anti-VEGF injections.
More >

News-Medical.net – September 2014

 
News-Medical-Net

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics More >

————————————————

Published Articles
Stereotatic Radiotherapy for Wet Age-Related Macular Degeneration (INTREPID): Influence of Baseline Characteristics on Clinical Response

Published ahead of print, RETINA, August 2014. Download >

Treating Neovascular AMD

Published in Expert Reviews of Ophthalmology, 2014. Download >

INTREPID Study One Year Results

Published in Ophthalmology, September 2013. Download >

WHAT IS AMD?

Age-Related Macular Degeneration (AMD) is a progressive disease that causes loss of central vision leading to blindness. It is the primary cause of vision loss for seniors in the industrialized world. While there is no cure for AMD, the Oraya Therapy™ for Wet AMD is an exciting new treatment.   More >

WHO IS ORAYA?

Founded in 2007, Oraya® Therapeutics, Inc. is a privately held company developing an innovative and non-invasive therapy designed to advance the treatment options for wet AMD.  More >

WHY ORAYA THERAPY?

Physicians and patients require a new option and a new vision for the treatment of wet AMD. Oraya Therapy— intended as a one-time, non-invasive procedure—uses a low-voltage, stereotactic approach. It delivers precisely controlled X-rays confined to the diseased area of interest, sparing the surrounding structures of the eye.  More >

© 2014 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.